Analysts Expect Breakeven For Verona Pharma Plc (NASDAQ:VRNA) Before Long
Analysts Expect Breakeven For Verona Pharma Plc (NASDAQ:VRNA) Before Long
With the business potentially at an important milestone, we thought we'd take a closer look at Verona Pharma plc's (NASDAQ:VRNA) future prospects. Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's loss has recently broadened since it announced a US$54m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$125m, moving it further away from breakeven. Many investors are wondering about the rate at which Verona Pharma will turn a profit, with the big question being "when will the company breakeven?" We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
随着业务可能进入一个重要的里程碑,我们认为我们应该更加关注维罗纳制药股份有限公司(NASDAQ:VRNA)未来的前景。维罗纳制药股份有限公司是一家临床阶段的生物制药公司,专注于开发和商业化治疗呼吸系统疾病的疗法,这些疾病存在未满足的医疗需求。自最近的完整财年宣布5400万美元的亏损以来,该公司的亏损已经扩大,相比最新的过去12个月的亏损达到了1.25亿美元,这将其进一步远离盈亏平衡点。许多投资者想知道维罗纳制药何时能盈利,有一个重要的问题是“公司何时能盈亏平衡?”我们概述了行业分析师对该公司的预期、公司盈亏平衡的年份以及其隐含的增长率。
According to the 5 industry analysts covering Verona Pharma, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$60m in 2026. Therefore, the company is expected to breakeven roughly 2 years from today. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. It turns out an average annual growth rate of 66% is expected, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
根据覆盖维罗纳制药的5位行业分析师的观点,达成共识即将到来,他们预计公司将在2025年承担最终的亏损,然后在2026年产生6000万美元的正利润。因此,该公司预计将于今天起2年左右实现盈亏平衡。为了达到盈亏平衡的日期,我们计算了该公司必须以年度复合增长率增长的速度。结果表明,该公司预计年平均增长率将达到66%,这是非常乐观的。如果这个速度被认为过于激进,该公司的盈利时间可能比分析师预计要晚得多。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240810/0-a59b12aca7d59fad0797b36b9a12f24e-0-5d7d1a833853f8b77372a89005806285.png/big)
Underlying developments driving Verona Pharma's growth isn't the focus of this broad overview, but, take into account that generally pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
推动维罗纳制药增长的潜在因素并不是这个广泛概述的重点,但是需要考虑到制药业通常根据产品开发阶段有不规则的现金流动。这意味着,大规模的即将到来的增长率并非不寻常,因为该公司正在开始收获早期投资的成果。
One thing we'd like to point out is that The company has managed its capital judiciously, with debt making up 22% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.
我们想指出的一件事是,该公司明智地管理了资本,债务占股本的22%。这意味着,它主要从股本资金融资其运营,并且其低债务义务降低了投资亏损公司的风险。
Next Steps:
下一步:
This article is not intended to be a comprehensive analysis on Verona Pharma, so if you are interested in understanding the company at a deeper level, take a look at Verona Pharma's company page on Simply Wall St. We've also put together a list of key factors you should further research:
本文不旨在对维罗纳制药进行全面分析,因此,如果您有兴趣深入了解该公司,请查看Simply Wall St上的维罗纳制药公司页面。我们还汇总了您应进一步研究的关键因素列表:
- Historical Track Record: What has Verona Pharma's performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Verona Pharma's board and the CEO's background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
- 历史业绩:维罗纳制药过去的表现如何?在过去的业绩分析中进行更详细的分析,并查看我们分析的免费视觉呈现,以获得更清晰的了解。
- 管理团队:经验丰富的管理团队能够增加我们对业务的信心——请看看谁在维罗纳制药的董事会上,以及首席执行官的背景。
- 其他高表现的股票:是否有其他表现更好的股票并具有经过验证的历史记录?查看这里的免费列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。